Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Annovis Bio ( (ANVS) ).
On October 10, 2025, Annovis Bio, Inc. announced a registered direct offering of 4,000,000 shares of its common stock, expected to close by October 14, 2025, with anticipated gross proceeds of approximately $6 million. The proceeds will be used for the continued clinical development of its lead compound Buntanetap in a Phase 3 study for Alzheimer’s disease, as well as for working capital and general corporate purposes. This offering positions Annovis to further its mission in addressing neurodegenerative diseases and potentially enhances its market standing by advancing its clinical programs.
The most recent analyst rating on (ANVS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.
Spark’s Take on ANVS Stock
According to Spark, TipRanks’ AI Analyst, ANVS is a Underperform.
Annovis Bio’s overall stock score reflects significant financial challenges with zero revenue and consistent losses, offset slightly by a debt-free balance sheet. Technical indicators suggest a bearish outlook, and valuation metrics are unattractive. Corporate events create a mixed picture, with regulatory compliance issues countered by progress in drug development. The stock remains speculative, relying heavily on future R&D success.
To see Spark’s full report on ANVS stock, click here.
More about Annovis Bio
Annovis Bio, Inc., based in Malvern, Pennsylvania, is a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
Average Trading Volume: 512,072
Technical Sentiment Signal: Sell
Current Market Cap: $33.13M
Learn more about ANVS stock on TipRanks’ Stock Analysis page.